Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessôa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Cheinquer H, Pathan R, Dong Y, Trylesinski A. Piratvisuth T, et al. PLoS One. 2013;8(2):e54279. doi: 10.1371/journal.pone.0054279. Epub 2013 Feb 4. PLoS One. 2013. PMID: 23390496 Free PMC article. Clinical Trial.
Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy.
Piratvisuth T, Komolmit P, Chan HL, Tanwandee T, Sukeepaisarnjaroen W, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Manns M, Uddin A, Dong Y, Trylesinski A. Piratvisuth T, et al. Drugs Context. 2016 Apr 22;5:212294. doi: 10.7573/dic.212294. eCollection 2016. Drugs Context. 2016. PMID: 27403192 Free PMC article.
Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.
Sonneveld MJ, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Liaw YF, Hansen BE, Choi H, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Knegt RJ, Janssen HLA. Sonneveld MJ, et al. Among authors: piratvisuth t. Lancet Gastroenterol Hepatol. 2019 Jul;4(7):538-544. doi: 10.1016/S2468-1253(19)30087-1. Epub 2019 Apr 9. Lancet Gastroenterol Hepatol. 2019. PMID: 30975477
Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study.
Sonneveld MJ, Hansen BE, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, de Knegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA; SONIC-B Study Group. Sonneveld MJ, et al. Among authors: piratvisuth t. J Infect Dis. 2022 Jun 1;225(11):1967-1973. doi: 10.1093/infdis/jiaa192. J Infect Dis. 2022. PMID: 32318704 Free PMC article.
Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis.
Sonneveld MJ, Brouwer WP, Hansen BE, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, Choi H, de Knegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA; SONIC-B Study Group. Sonneveld MJ, et al. Among authors: piratvisuth t. Aliment Pharmacol Ther. 2020 Oct;52(8):1399-1406. doi: 10.1111/apt.16067. Epub 2020 Sep 4. Aliment Pharmacol Ther. 2020. PMID: 32886813 Free PMC article.
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B; CREATE study group. Sonneveld MJ, et al. Among authors: piratvisuth t. J Hepatol. 2022 May;76(5):1042-1050. doi: 10.1016/j.jhep.2022.01.007. Epub 2022 Jan 29. J Hepatol. 2022. PMID: 35092743 Free article.
124 results